May 6th 2024
Significant findings included a 100% biochemical recurrence-free rate at 24 months post-surgery in patients with high-risk localized prostate cancer.
Bristol Myers Squibb Reveals Promising Data for KarXT, a Potential Treatment for Schizophrenia
April 9th 2024A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.
Navigating the CBD Research Landscape: Unveiling Best Practices in the Post-MMCREA Era
March 14th 2024Although research on cannabinoids is now allowed in a growing number of countries, there are still a number of restrictions and corresponding licenses and permits required to work with these chemicals.
Benefits and Limitations of Strategies Used to Improve Clinical Development Productivity
March 13th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report including the potential benefits and limitations of novel trial designs and decentralized methodologies.
Contributing Factors to the Growing Gap in Access Between the US and Europe
March 11th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses findings from IQVIA's Global Trends in R&D 2024 report that shows why the US continued to lead in new drug launches in 2023.
The Biggest Challenges Facing Broader Adoption of Novel Cell and Gene Therapies
March 7th 2024In this Pharmaceutical Executive video interview, Murray Aitken, Executive Director of the IQVIA Institute for Human Data Science, discusses the biggest challenges facing the broader adoption of novel cell and gene therapies from IQVIA's Global Trends in R&D 2024 report.